# MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL)

> **NCT04157686** · PHASE3 · COMPLETED · sponsor: **Medy-Tox** · enrollment: 957 (actual)

## Conditions studied

- Glabellar Lines
- Lateral Canthal Lines

## Interventions

- **DRUG:** MT10109L Dose 1
- **DRUG:** MT10109L Dose 2
- **DRUG:** MT10109L Dose 1 + Dose 2

## Key facts

- **NCT ID:** NCT04157686
- **Lead sponsor:** Medy-Tox
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-23
- **Primary completion:** 2023-02-16
- **Final completion:** 2023-02-16
- **Target enrollment:** 957 (ACTUAL)
- **Last updated:** 2024-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04157686

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04157686, "MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04157686. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*